Skip to content Skip to footer
Subscribe Now
Ascendis Pharma
NEWS

Ascendis Pharma’s Yorvipath Receives the US FDA’s Approval to Treat Hypoparathyroidism 

Shots:      The US FDA has approved Yorvipath (QD) tablets for treating hypoparathyroidism patients, with its initial supply planned during Q1’25  The approval was supported by the P-II (PaTH Forward) as well as P-III (PaTHway) clinical trials conducted worldwide   Ascendis will further introduce the US Ascendis Signature Access Program (A.S.A.P.) for treatment support & financial assistance…
August 9, 2024

Read more

PharmaShots Interview In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space
VIEWPOINTS

PharmaShots Interview: In Conversation with Amolyt’s CEO, Thierry Abribat, Where he Shares Insights on Amolyt as a Key Player in Hypoparathyroidism Space

Shots: Thierry spoke about the IND clearance of its lead candidate in hypoparathyroidism and the company’s clinical trial plans for rare endocrine and related diseases Thierry also communicated about the closing of funding Series B equity financing round The interview gives a deeper understanding of Hypoparathyroidism and its treatment options Smriti: What did this Investigational…
June 1, 2022

Read more

Viewpoints_Thierry Abribat
VIEWPOINTS

PharmaShots Interview: Amolyt Pharma’s Thierry Abribat Shares Insight on the Data of AZP-3601 for Hypoparathyroidism

In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer at Amolyt Pharma shares his views on the data from the P-I trial of AZP-3601 for the treatment of Hypoparathyroidism Shots: The P-I trial evaluates the safety, tolerability, PK, PD, and preliminary efficacy of AZP-3601 in 102 healthy volunteers including 52 in the SAD and 50 in the MAD cohorts…
December 15, 2021

Read more